Pharmaceutical collaboration between China and the West is increasing amidst geopolitical tensions.

This year, seven major pharmaceutical companies have invested over $3.15 billion in upfront cash and equity to license or acquire drug molecules from China.

These companies are expanding their presence in China to discover promising drug candidates, which indicates a strategic shift in the global pharmaceutical landscape.

The potential impact of the incoming Trump administration on these partnerships is being closely watched by industry observers, as it could reshape international pharmaceutical collaboration dynamics.